nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—penis—atherosclerosis	0.0668	0.324	CbGeAlD
Lithium—IMPA1—cardiovascular system—atherosclerosis	0.0168	0.0815	CbGeAlD
Lithium—GSK3B—connective tissue—atherosclerosis	0.0142	0.0689	CbGeAlD
Lithium—GSK3B—cardiovascular system—atherosclerosis	0.0124	0.06	CbGeAlD
Lithium—GSK3A—connective tissue—atherosclerosis	0.0124	0.0599	CbGeAlD
Lithium—IMPA2—adipose tissue—atherosclerosis	0.0111	0.0539	CbGeAlD
Lithium—GSK3B—adipose tissue—atherosclerosis	0.0109	0.0529	CbGeAlD
Lithium—GSK3A—cardiovascular system—atherosclerosis	0.0108	0.0522	CbGeAlD
Lithium—IMPA1—liver—atherosclerosis	0.0104	0.0504	CbGeAlD
Lithium—GSK3A—adipose tissue—atherosclerosis	0.00948	0.046	CbGeAlD
Lithium—GRIA3—liver—atherosclerosis	0.00883	0.0428	CbGeAlD
Lithium—IMPA2—liver—atherosclerosis	0.00779	0.0378	CbGeAlD
Lithium—GSK3B—liver—atherosclerosis	0.00765	0.0371	CbGeAlD
Lithium—Sexual dysfunction—Simvastatin—atherosclerosis	0.0067	0.0228	CcSEcCtD
Lithium—GSK3A—liver—atherosclerosis	0.00665	0.0323	CbGeAlD
Lithium—Sexual dysfunction—Pravastatin—atherosclerosis	0.00606	0.0207	CcSEcCtD
Lithium—Memory impairment—Rosuvastatin—atherosclerosis	0.00604	0.0206	CcSEcCtD
Lithium—Hypothyroidism—Niacin—atherosclerosis	0.00538	0.0183	CcSEcCtD
Lithium—Memory impairment—Lovastatin—atherosclerosis	0.00512	0.0174	CcSEcCtD
Lithium—Memory impairment—Ezetimibe—atherosclerosis	0.00502	0.0171	CcSEcCtD
Lithium—Memory impairment—Simvastatin—atherosclerosis	0.00479	0.0163	CcSEcCtD
Lithium—Skin ulcer—Niacin—atherosclerosis	0.00443	0.0151	CcSEcCtD
Lithium—Memory impairment—Pravastatin—atherosclerosis	0.00433	0.0148	CcSEcCtD
Lithium—Hypertonia—Rosuvastatin—atherosclerosis	0.00416	0.0142	CcSEcCtD
Lithium—Muscle twitching—Niacin—atherosclerosis	0.00351	0.012	CcSEcCtD
Lithium—Urine output increased—Niacin—atherosclerosis	0.00312	0.0106	CcSEcCtD
Lithium—Swelling—Simvastatin—atherosclerosis	0.00309	0.0105	CcSEcCtD
Lithium—Muscular weakness—Rosuvastatin—atherosclerosis	0.00304	0.0103	CcSEcCtD
Lithium—Hypertonia—Niacin—atherosclerosis	0.00302	0.0103	CcSEcCtD
Lithium—Polyuria—Niacin—atherosclerosis	0.00285	0.00972	CcSEcCtD
Lithium—Gastritis—Ezetimibe—atherosclerosis	0.00253	0.00863	CcSEcCtD
Lithium—Muscular weakness—Ezetimibe—atherosclerosis	0.00252	0.0086	CcSEcCtD
Lithium—Gastritis—Simvastatin—atherosclerosis	0.00241	0.00823	CcSEcCtD
Lithium—Muscular weakness—Simvastatin—atherosclerosis	0.00241	0.0082	CcSEcCtD
Lithium—Erectile dysfunction—Lovastatin—atherosclerosis	0.00232	0.00791	CcSEcCtD
Lithium—Dry skin—Niacin—atherosclerosis	0.0023	0.00782	CcSEcCtD
Lithium—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00228	0.00776	CcSEcCtD
Lithium—Dry skin—Pravastatin—atherosclerosis	0.00226	0.0077	CcSEcCtD
Lithium—Muscular weakness—Niacin—atherosclerosis	0.00221	0.00753	CcSEcCtD
Lithium—Muscular weakness—Pravastatin—atherosclerosis	0.00218	0.00741	CcSEcCtD
Lithium—Erectile dysfunction—Simvastatin—atherosclerosis	0.00217	0.0074	CcSEcCtD
Lithium—Arrhythmia—Rosuvastatin—atherosclerosis	0.00213	0.00725	CcSEcCtD
Lithium—Flatulence—Rosuvastatin—atherosclerosis	0.00204	0.00696	CcSEcCtD
Lithium—Erectile dysfunction—Niacin—atherosclerosis	0.00199	0.00679	CcSEcCtD
Lithium—Erectile dysfunction—Pravastatin—atherosclerosis	0.00196	0.00669	CcSEcCtD
Lithium—Weight increased—Pravastatin—atherosclerosis	0.00194	0.00661	CcSEcCtD
Lithium—Weight decreased—Pravastatin—atherosclerosis	0.00193	0.00657	CcSEcCtD
Lithium—Angioedema—Rosuvastatin—atherosclerosis	0.00189	0.00645	CcSEcCtD
Lithium—Alopecia—Lovastatin—atherosclerosis	0.00178	0.00608	CcSEcCtD
Lithium—Arthralgia—Rosuvastatin—atherosclerosis	0.00176	0.00601	CcSEcCtD
Lithium—Alopecia—Ezetimibe—atherosclerosis	0.00175	0.00596	CcSEcCtD
Lithium—Flatulence—Lovastatin—atherosclerosis	0.00173	0.0059	CcSEcCtD
Lithium—Dysgeusia—Lovastatin—atherosclerosis	0.00172	0.00586	CcSEcCtD
Lithium—Confusional state—Rosuvastatin—atherosclerosis	0.00171	0.00581	CcSEcCtD
Lithium—Flatulence—Ezetimibe—atherosclerosis	0.0017	0.00578	CcSEcCtD
Lithium—Alopecia—Simvastatin—atherosclerosis	0.00167	0.00568	CcSEcCtD
Lithium—Vision blurred—Lovastatin—atherosclerosis	0.00166	0.00564	CcSEcCtD
Lithium—Tremor—Lovastatin—atherosclerosis	0.00165	0.00561	CcSEcCtD
Lithium—Flatulence—Simvastatin—atherosclerosis	0.00162	0.00552	CcSEcCtD
Lithium—Tinnitus—Niacin—atherosclerosis	0.00162	0.00551	CcSEcCtD
Lithium—Dysgeusia—Simvastatin—atherosclerosis	0.00161	0.00548	CcSEcCtD
Lithium—Angioedema—Lovastatin—atherosclerosis	0.0016	0.00547	CcSEcCtD
Lithium—Tinnitus—Pravastatin—atherosclerosis	0.00159	0.00542	CcSEcCtD
Lithium—Vertigo—Lovastatin—atherosclerosis	0.00158	0.00538	CcSEcCtD
Lithium—Angioedema—Ezetimibe—atherosclerosis	0.00157	0.00536	CcSEcCtD
Lithium—Vision blurred—Simvastatin—atherosclerosis	0.00155	0.00528	CcSEcCtD
Lithium—Arrhythmia—Niacin—atherosclerosis	0.00155	0.00528	CcSEcCtD
Lithium—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00154	0.00525	CcSEcCtD
Lithium—Tremor—Simvastatin—atherosclerosis	0.00154	0.00525	CcSEcCtD
Lithium—Alopecia—Niacin—atherosclerosis	0.00153	0.00522	CcSEcCtD
Lithium—Arrhythmia—Pravastatin—atherosclerosis	0.00152	0.00519	CcSEcCtD
Lithium—Alopecia—Pravastatin—atherosclerosis	0.00151	0.00514	CcSEcCtD
Lithium—Angioedema—Simvastatin—atherosclerosis	0.0015	0.00512	CcSEcCtD
Lithium—Arthralgia—Lovastatin—atherosclerosis	0.0015	0.0051	CcSEcCtD
Lithium—Dyspepsia—Rosuvastatin—atherosclerosis	0.00149	0.00507	CcSEcCtD
Lithium—Flatulence—Niacin—atherosclerosis	0.00149	0.00507	CcSEcCtD
Lithium—Discomfort—Lovastatin—atherosclerosis	0.00148	0.00503	CcSEcCtD
Lithium—Vertigo—Simvastatin—atherosclerosis	0.00148	0.00503	CcSEcCtD
Lithium—Arthralgia—Ezetimibe—atherosclerosis	0.00147	0.005	CcSEcCtD
Lithium—Flatulence—Pravastatin—atherosclerosis	0.00146	0.00499	CcSEcCtD
Lithium—Dry mouth—Lovastatin—atherosclerosis	0.00146	0.00498	CcSEcCtD
Lithium—Dysgeusia—Pravastatin—atherosclerosis	0.00145	0.00496	CcSEcCtD
Lithium—Discomfort—Ezetimibe—atherosclerosis	0.00145	0.00494	CcSEcCtD
Lithium—Confusional state—Lovastatin—atherosclerosis	0.00145	0.00493	CcSEcCtD
Lithium—Dry mouth—Ezetimibe—atherosclerosis	0.00143	0.00489	CcSEcCtD
Lithium—Vision blurred—Niacin—atherosclerosis	0.00142	0.00484	CcSEcCtD
Lithium—Confusional state—Ezetimibe—atherosclerosis	0.00142	0.00483	CcSEcCtD
Lithium—Vision blurred—Pravastatin—atherosclerosis	0.0014	0.00477	CcSEcCtD
Lithium—Arthralgia—Simvastatin—atherosclerosis	0.0014	0.00477	CcSEcCtD
Lithium—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00139	0.00475	CcSEcCtD
Lithium—Tremor—Pravastatin—atherosclerosis	0.00139	0.00474	CcSEcCtD
Lithium—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00138	0.00471	CcSEcCtD
Lithium—Discomfort—Simvastatin—atherosclerosis	0.00138	0.00471	CcSEcCtD
Lithium—Angioedema—Niacin—atherosclerosis	0.00138	0.0047	CcSEcCtD
Lithium—Anorexia—Lovastatin—atherosclerosis	0.00137	0.00466	CcSEcCtD
Lithium—Angioedema—Pravastatin—atherosclerosis	0.00136	0.00462	CcSEcCtD
Lithium—Vertigo—Niacin—atherosclerosis	0.00136	0.00462	CcSEcCtD
Lithium—Syncope—Niacin—atherosclerosis	0.00135	0.00461	CcSEcCtD
Lithium—Confusional state—Simvastatin—atherosclerosis	0.00135	0.00461	CcSEcCtD
Lithium—Oedema—Simvastatin—atherosclerosis	0.00134	0.00457	CcSEcCtD
Lithium—Abdominal pain—Rosuvastatin—atherosclerosis	0.00134	0.00456	CcSEcCtD
Lithium—Vertigo—Pravastatin—atherosclerosis	0.00133	0.00455	CcSEcCtD
Lithium—Loss of consciousness—Niacin—atherosclerosis	0.00133	0.00452	CcSEcCtD
Lithium—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00131	0.00445	CcSEcCtD
Lithium—Arthralgia—Niacin—atherosclerosis	0.00128	0.00438	CcSEcCtD
Lithium—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00128	0.00437	CcSEcCtD
Lithium—Anorexia—Simvastatin—atherosclerosis	0.00128	0.00436	CcSEcCtD
Lithium—Arthralgia—Pravastatin—atherosclerosis	0.00126	0.00431	CcSEcCtD
Lithium—Dyspepsia—Lovastatin—atherosclerosis	0.00126	0.0043	CcSEcCtD
Lithium—Dry mouth—Niacin—atherosclerosis	0.00126	0.00428	CcSEcCtD
Lithium—Discomfort—Pravastatin—atherosclerosis	0.00125	0.00426	CcSEcCtD
Lithium—Decreased appetite—Lovastatin—atherosclerosis	0.00125	0.00425	CcSEcCtD
Lithium—Dyspepsia—Ezetimibe—atherosclerosis	0.00124	0.00422	CcSEcCtD
Lithium—Fatigue—Lovastatin—atherosclerosis	0.00124	0.00421	CcSEcCtD
Lithium—Oedema—Niacin—atherosclerosis	0.00123	0.0042	CcSEcCtD
Lithium—Confusional state—Pravastatin—atherosclerosis	0.00122	0.00417	CcSEcCtD
Lithium—Decreased appetite—Ezetimibe—atherosclerosis	0.00122	0.00416	CcSEcCtD
Lithium—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00122	0.00416	CcSEcCtD
Lithium—Asthenia—Rosuvastatin—atherosclerosis	0.00121	0.00414	CcSEcCtD
Lithium—Oedema—Pravastatin—atherosclerosis	0.00121	0.00413	CcSEcCtD
Lithium—Fatigue—Ezetimibe—atherosclerosis	0.00121	0.00413	CcSEcCtD
Lithium—Shock—Niacin—atherosclerosis	0.00121	0.00413	CcSEcCtD
Lithium—Feeling abnormal—Lovastatin—atherosclerosis	0.00118	0.00403	CcSEcCtD
Lithium—Dyspepsia—Simvastatin—atherosclerosis	0.00118	0.00402	CcSEcCtD
Lithium—Anorexia—Niacin—atherosclerosis	0.00117	0.004	CcSEcCtD
Lithium—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00117	0.00399	CcSEcCtD
Lithium—Decreased appetite—Simvastatin—atherosclerosis	0.00117	0.00397	CcSEcCtD
Lithium—Feeling abnormal—Ezetimibe—atherosclerosis	0.00116	0.00395	CcSEcCtD
Lithium—Diarrhoea—Rosuvastatin—atherosclerosis	0.00116	0.00394	CcSEcCtD
Lithium—Fatigue—Simvastatin—atherosclerosis	0.00116	0.00394	CcSEcCtD
Lithium—Anorexia—Pravastatin—atherosclerosis	0.00116	0.00394	CcSEcCtD
Lithium—Hypotension—Niacin—atherosclerosis	0.00115	0.00392	CcSEcCtD
Lithium—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00115	0.00392	CcSEcCtD
Lithium—Abdominal pain—Lovastatin—atherosclerosis	0.00113	0.00386	CcSEcCtD
Lithium—Body temperature increased—Lovastatin—atherosclerosis	0.00113	0.00386	CcSEcCtD
Lithium—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00112	0.00382	CcSEcCtD
Lithium—Dizziness—Rosuvastatin—atherosclerosis	0.00112	0.00381	CcSEcCtD
Lithium—Abdominal pain—Ezetimibe—atherosclerosis	0.00111	0.00379	CcSEcCtD
Lithium—Body temperature increased—Ezetimibe—atherosclerosis	0.00111	0.00379	CcSEcCtD
Lithium—Feeling abnormal—Simvastatin—atherosclerosis	0.0011	0.00377	CcSEcCtD
Lithium—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.0011	0.00376	CcSEcCtD
Lithium—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0011	0.00374	CcSEcCtD
Lithium—Somnolence—Niacin—atherosclerosis	0.00109	0.00373	CcSEcCtD
Lithium—Dyspepsia—Niacin—atherosclerosis	0.00108	0.00369	CcSEcCtD
Lithium—Decreased appetite—Niacin—atherosclerosis	0.00107	0.00365	CcSEcCtD
Lithium—Dyspepsia—Pravastatin—atherosclerosis	0.00107	0.00364	CcSEcCtD
Lithium—Rash—Rosuvastatin—atherosclerosis	0.00107	0.00363	CcSEcCtD
Lithium—Dermatitis—Rosuvastatin—atherosclerosis	0.00107	0.00363	CcSEcCtD
Lithium—Body temperature increased—Simvastatin—atherosclerosis	0.00106	0.00361	CcSEcCtD
Lithium—Abdominal pain—Simvastatin—atherosclerosis	0.00106	0.00361	CcSEcCtD
Lithium—Headache—Rosuvastatin—atherosclerosis	0.00106	0.00361	CcSEcCtD
Lithium—Decreased appetite—Pravastatin—atherosclerosis	0.00105	0.00359	CcSEcCtD
Lithium—Fatigue—Pravastatin—atherosclerosis	0.00105	0.00356	CcSEcCtD
Lithium—Asthenia—Lovastatin—atherosclerosis	0.00103	0.0035	CcSEcCtD
Lithium—Asthenia—Ezetimibe—atherosclerosis	0.00101	0.00344	CcSEcCtD
Lithium—Gastrointestinal pain—Niacin—atherosclerosis	0.00101	0.00343	CcSEcCtD
Lithium—Nausea—Rosuvastatin—atherosclerosis	0.001	0.00342	CcSEcCtD
Lithium—Feeling abnormal—Pravastatin—atherosclerosis	0.000999	0.0034	CcSEcCtD
Lithium—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000991	0.00338	CcSEcCtD
Lithium—Diarrhoea—Lovastatin—atherosclerosis	0.000981	0.00334	CcSEcCtD
Lithium—Abdominal pain—Niacin—atherosclerosis	0.000973	0.00332	CcSEcCtD
Lithium—Body temperature increased—Niacin—atherosclerosis	0.000973	0.00332	CcSEcCtD
Lithium—Asthenia—Simvastatin—atherosclerosis	0.000962	0.00328	CcSEcCtD
Lithium—Diarrhoea—Ezetimibe—atherosclerosis	0.000962	0.00328	CcSEcCtD
Lithium—Abdominal pain—Pravastatin—atherosclerosis	0.000958	0.00327	CcSEcCtD
Lithium—Body temperature increased—Pravastatin—atherosclerosis	0.000958	0.00327	CcSEcCtD
Lithium—Dizziness—Lovastatin—atherosclerosis	0.000948	0.00323	CcSEcCtD
Lithium—Dizziness—Ezetimibe—atherosclerosis	0.00093	0.00317	CcSEcCtD
Lithium—Diarrhoea—Simvastatin—atherosclerosis	0.000917	0.00313	CcSEcCtD
Lithium—Vomiting—Lovastatin—atherosclerosis	0.000911	0.00311	CcSEcCtD
Lithium—Rash—Lovastatin—atherosclerosis	0.000904	0.00308	CcSEcCtD
Lithium—Dermatitis—Lovastatin—atherosclerosis	0.000903	0.00308	CcSEcCtD
Lithium—Headache—Lovastatin—atherosclerosis	0.000898	0.00306	CcSEcCtD
Lithium—Vomiting—Ezetimibe—atherosclerosis	0.000894	0.00305	CcSEcCtD
Lithium—Dizziness—Simvastatin—atherosclerosis	0.000887	0.00302	CcSEcCtD
Lithium—Rash—Ezetimibe—atherosclerosis	0.000887	0.00302	CcSEcCtD
Lithium—Dermatitis—Ezetimibe—atherosclerosis	0.000886	0.00302	CcSEcCtD
Lithium—Asthenia—Niacin—atherosclerosis	0.000883	0.00301	CcSEcCtD
Lithium—Headache—Ezetimibe—atherosclerosis	0.000881	0.003	CcSEcCtD
Lithium—Asthenia—Pravastatin—atherosclerosis	0.00087	0.00296	CcSEcCtD
Lithium—Vomiting—Simvastatin—atherosclerosis	0.000853	0.00291	CcSEcCtD
Lithium—Nausea—Lovastatin—atherosclerosis	0.000852	0.0029	CcSEcCtD
Lithium—Rash—Simvastatin—atherosclerosis	0.000845	0.00288	CcSEcCtD
Lithium—Dermatitis—Simvastatin—atherosclerosis	0.000845	0.00288	CcSEcCtD
Lithium—Diarrhoea—Niacin—atherosclerosis	0.000842	0.00287	CcSEcCtD
Lithium—Headache—Simvastatin—atherosclerosis	0.00084	0.00286	CcSEcCtD
Lithium—Nausea—Ezetimibe—atherosclerosis	0.000835	0.00285	CcSEcCtD
Lithium—Diarrhoea—Pravastatin—atherosclerosis	0.000829	0.00283	CcSEcCtD
Lithium—Dizziness—Niacin—atherosclerosis	0.000814	0.00277	CcSEcCtD
Lithium—Dizziness—Pravastatin—atherosclerosis	0.000802	0.00273	CcSEcCtD
Lithium—Nausea—Simvastatin—atherosclerosis	0.000796	0.00271	CcSEcCtD
Lithium—Vomiting—Niacin—atherosclerosis	0.000783	0.00267	CcSEcCtD
Lithium—Rash—Niacin—atherosclerosis	0.000776	0.00265	CcSEcCtD
Lithium—Dermatitis—Niacin—atherosclerosis	0.000776	0.00264	CcSEcCtD
Lithium—Headache—Niacin—atherosclerosis	0.000771	0.00263	CcSEcCtD
Lithium—Vomiting—Pravastatin—atherosclerosis	0.000771	0.00263	CcSEcCtD
Lithium—Rash—Pravastatin—atherosclerosis	0.000764	0.0026	CcSEcCtD
Lithium—Dermatitis—Pravastatin—atherosclerosis	0.000764	0.0026	CcSEcCtD
Lithium—Headache—Pravastatin—atherosclerosis	0.000759	0.00259	CcSEcCtD
Lithium—Nausea—Niacin—atherosclerosis	0.000731	0.00249	CcSEcCtD
Lithium—Nausea—Pravastatin—atherosclerosis	0.00072	0.00245	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—APOC3—atherosclerosis	0.00017	0.000339	CbGpPWpGaD
Lithium—GSK3B—Immune System—CYBA—atherosclerosis	0.00017	0.000339	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PPARG—atherosclerosis	0.000169	0.000338	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LDLR—atherosclerosis	0.000169	0.000337	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR4—atherosclerosis	0.000168	0.000336	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—IGF1—atherosclerosis	0.000167	0.000335	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOA2—atherosclerosis	0.000167	0.000333	CbGpPWpGaD
Lithium—GSK3B—Disease—NCF1—atherosclerosis	0.000166	0.000333	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—INS—atherosclerosis	0.000166	0.000331	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL18—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL3—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—atherosclerosis	0.000165	0.000329	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—atherosclerosis	0.000164	0.000328	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—atherosclerosis	0.000164	0.000328	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—MAPK3—atherosclerosis	0.000164	0.000327	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP9—atherosclerosis	0.000163	0.000327	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—IL6—atherosclerosis	0.000163	0.000326	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—atherosclerosis	0.000163	0.000326	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—atherosclerosis	0.000162	0.000324	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—atherosclerosis	0.000162	0.000324	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—atherosclerosis	0.000162	0.000323	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—atherosclerosis	0.000161	0.000323	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—atherosclerosis	0.000161	0.000322	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—STAT3—atherosclerosis	0.000161	0.000321	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—atherosclerosis	0.000159	0.000318	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—UTS2—atherosclerosis	0.000159	0.000317	CbGpPWpGaD
Lithium—GSK3A—Immune System—AGER—atherosclerosis	0.000158	0.000316	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR2—atherosclerosis	0.000158	0.000316	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40—atherosclerosis	0.000158	0.000316	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NCF1—atherosclerosis	0.000158	0.000315	CbGpPWpGaD
Lithium—GSK3A—Immune System—PRKCG—atherosclerosis	0.000157	0.000313	CbGpPWpGaD
Lithium—GSK3B—Disease—CYBA—atherosclerosis	0.000157	0.000313	CbGpPWpGaD
Lithium—GSK3A—Disease—APOB—atherosclerosis	0.000156	0.000311	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP2—atherosclerosis	0.000155	0.00031	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ICAM1—atherosclerosis	0.000155	0.000309	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MAPK3—atherosclerosis	0.000153	0.000307	CbGpPWpGaD
Lithium—GSK3B—Disease—PARP1—atherosclerosis	0.000153	0.000306	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD36—atherosclerosis	0.000153	0.000306	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CX3CR1—atherosclerosis	0.000152	0.000304	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASR—atherosclerosis	0.000152	0.000304	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—atherosclerosis	0.000152	0.000304	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—atherosclerosis	0.000152	0.000304	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—atherosclerosis	0.000152	0.000304	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—IL6—atherosclerosis	0.000152	0.000303	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—atherosclerosis	0.000151	0.000301	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CX3CL1—atherosclerosis	0.000149	0.000298	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—atherosclerosis	0.000149	0.000298	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EDNRA—atherosclerosis	0.000149	0.000298	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCR2—atherosclerosis	0.000149	0.000298	CbGpPWpGaD
Lithium—GSK3A—Disease—LPL—atherosclerosis	0.000149	0.000297	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—atherosclerosis	0.000149	0.000297	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—atherosclerosis	0.000149	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CYBA—atherosclerosis	0.000148	0.000296	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—atherosclerosis	0.000147	0.000293	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—atherosclerosis	0.000146	0.000291	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PARP1—atherosclerosis	0.000145	0.00029	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GHRL—atherosclerosis	0.000145	0.00029	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLAT—atherosclerosis	0.000145	0.00029	CbGpPWpGaD
Lithium—GSK3A—Disease—PRKCG—atherosclerosis	0.000145	0.000289	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—atherosclerosis	0.000144	0.000287	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD14—atherosclerosis	0.000143	0.000285	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CNR2—atherosclerosis	0.000142	0.000283	CbGpPWpGaD
Lithium—GSK3A—Immune System—PDGFB—atherosclerosis	0.000141	0.000282	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—atherosclerosis	0.000141	0.000281	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—atherosclerosis	0.00014	0.00028	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MAPK3—atherosclerosis	0.000139	0.000278	CbGpPWpGaD
Lithium—GSK3A—Immune System—CRP—atherosclerosis	0.000138	0.000276	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NFKB1—atherosclerosis	0.000138	0.000276	CbGpPWpGaD
Lithium—GSK3B—Immune System—VCAM1—atherosclerosis	0.000138	0.000275	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK8—atherosclerosis	0.000136	0.000271	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—atherosclerosis	0.000135	0.000269	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—atherosclerosis	0.000135	0.000269	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—atherosclerosis	0.000134	0.000268	CbGpPWpGaD
Lithium—GSK3B—Immune System—SOCS3—atherosclerosis	0.000134	0.000267	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NFKB1—atherosclerosis	0.000132	0.000265	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—atherosclerosis	0.000132	0.000265	CbGpPWpGaD
Lithium—GSK3A—Disease—PDGFB—atherosclerosis	0.00013	0.000261	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—atherosclerosis	0.000129	0.000257	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KNG1—atherosclerosis	0.000127	0.000255	CbGpPWpGaD
Lithium—GSK3A—Immune System—ICAM1—atherosclerosis	0.000127	0.000254	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGTR1—atherosclerosis	0.000127	0.000253	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VWF—atherosclerosis	0.000126	0.000252	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOC3—atherosclerosis	0.000125	0.000251	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—atherosclerosis	0.000125	0.000249	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LDLR—atherosclerosis	0.000125	0.000249	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—atherosclerosis	0.000125	0.000249	CbGpPWpGaD
Lithium—GSK3A—Disease—CAV1—atherosclerosis	0.000124	0.000247	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PLG—atherosclerosis	0.000123	0.000247	CbGpPWpGaD
Lithium—GSK3A—Disease—APOA1—atherosclerosis	0.000123	0.000246	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL18—atherosclerosis	0.000122	0.000243	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL3—atherosclerosis	0.000122	0.000243	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—atherosclerosis	0.000121	0.000242	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—atherosclerosis	0.00012	0.000239	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MAPK3—atherosclerosis	0.000118	0.000237	CbGpPWpGaD
Lithium—GSK3B—Immune System—AGER—atherosclerosis	0.000117	0.000234	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SOCS3—atherosclerosis	0.000117	0.000234	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—atherosclerosis	0.000117	0.000233	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NCF1—atherosclerosis	0.000117	0.000233	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—atherosclerosis	0.000116	0.000232	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRKCG—atherosclerosis	0.000116	0.000231	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—atherosclerosis	0.000116	0.000231	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NFKB1—atherosclerosis	0.000115	0.000231	CbGpPWpGaD
Lithium—GSK3B—Disease—APOB—atherosclerosis	0.000115	0.00023	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD36—atherosclerosis	0.000113	0.000226	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP3—atherosclerosis	0.000113	0.000226	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—atherosclerosis	0.000112	0.000225	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—atherosclerosis	0.000112	0.000224	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCR2—atherosclerosis	0.00011	0.00022	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDNRA—atherosclerosis	0.00011	0.00022	CbGpPWpGaD
Lithium—GSK3B—Disease—LPL—atherosclerosis	0.00011	0.00022	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CYBA—atherosclerosis	0.00011	0.000219	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOB—atherosclerosis	0.000109	0.000218	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EDN1—atherosclerosis	0.000107	0.000215	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLAT—atherosclerosis	0.000107	0.000214	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PARP1—atherosclerosis	0.000107	0.000214	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GHRL—atherosclerosis	0.000107	0.000214	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—atherosclerosis	0.000107	0.000214	CbGpPWpGaD
Lithium—GSK3B—Disease—PRKCG—atherosclerosis	0.000107	0.000214	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL5—atherosclerosis	0.000107	0.000213	CbGpPWpGaD
Lithium—GSK3A—Disease—INS—atherosclerosis	0.000107	0.000213	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—atherosclerosis	0.000105	0.000209	CbGpPWpGaD
Lithium—GSK3B—Immune System—PDGFB—atherosclerosis	0.000104	0.000209	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LPL—atherosclerosis	0.000104	0.000208	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—atherosclerosis	0.000104	0.000207	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—atherosclerosis	0.000103	0.000207	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—atherosclerosis	0.000102	0.000204	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NFKB1—atherosclerosis	0.000102	0.000204	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—atherosclerosis	0.000102	0.000203	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRKCG—atherosclerosis	0.000101	0.000202	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK8—atherosclerosis	0.0001	0.0002	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MAPK3—atherosclerosis	9.91e-05	0.000198	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—atherosclerosis	9.9e-05	0.000198	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SPP1—atherosclerosis	9.87e-05	0.000197	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NFKB1—atherosclerosis	9.79e-05	0.000196	CbGpPWpGaD
Lithium—GSK3A—Disease—SERPINE1—atherosclerosis	9.79e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—atherosclerosis	9.78e-05	0.000195	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNG—atherosclerosis	9.66e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Disease—PDGFB—atherosclerosis	9.64e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—atherosclerosis	9.61e-05	0.000192	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—atherosclerosis	9.56e-05	0.000191	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—atherosclerosis	9.53e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KNG1—atherosclerosis	9.42e-05	0.000188	CbGpPWpGaD
Lithium—GSK3B—Immune System—ICAM1—atherosclerosis	9.38e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGTR1—atherosclerosis	9.36e-05	0.000187	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—atherosclerosis	9.34e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—atherosclerosis	9.22e-05	0.000184	CbGpPWpGaD
Lithium—GSK3B—Disease—CAV1—atherosclerosis	9.13e-05	0.000183	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFB—atherosclerosis	9.13e-05	0.000183	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLG—atherosclerosis	9.12e-05	0.000182	CbGpPWpGaD
Lithium—GSK3B—Disease—APOA1—atherosclerosis	9.11e-05	0.000182	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—atherosclerosis	8.98e-05	0.000179	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGT—atherosclerosis	8.91e-05	0.000178	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MAPK3—atherosclerosis	8.75e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—atherosclerosis	8.73e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LEP—atherosclerosis	8.73e-05	0.000175	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—atherosclerosis	8.66e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CAV1—atherosclerosis	8.65e-05	0.000173	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SOCS3—atherosclerosis	8.64e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOA1—atherosclerosis	8.63e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—atherosclerosis	8.61e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—atherosclerosis	8.59e-05	0.000172	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—atherosclerosis	8.55e-05	0.000171	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP3—atherosclerosis	8.34e-05	0.000167	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—atherosclerosis	8.34e-05	0.000167	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—atherosclerosis	8.31e-05	0.000166	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—F2—atherosclerosis	8.24e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOB—atherosclerosis	8.06e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Immune System—NFKB1—atherosclerosis	8.03e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—atherosclerosis	7.99e-05	0.00016	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDN1—atherosclerosis	7.94e-05	0.000159	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK8—atherosclerosis	7.9e-05	0.000158	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—atherosclerosis	7.88e-05	0.000158	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL5—atherosclerosis	7.88e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Disease—INS—atherosclerosis	7.87e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LPL—atherosclerosis	7.7e-05	0.000154	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—atherosclerosis	7.67e-05	0.000153	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKCG—atherosclerosis	7.49e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—INS—atherosclerosis	7.46e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL2—atherosclerosis	7.34e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SPP1—atherosclerosis	7.29e-05	0.000146	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—atherosclerosis	7.24e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Disease—SERPINE1—atherosclerosis	7.23e-05	0.000145	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—atherosclerosis	7.22e-05	0.000144	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1—atherosclerosis	7.22e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—atherosclerosis	7.13e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—atherosclerosis	6.91e-05	0.000138	CbGpPWpGaD
Lithium—GSK3A—Immune System—MAPK3—atherosclerosis	6.9e-05	0.000138	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SERPINE1—atherosclerosis	6.85e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFB—atherosclerosis	6.75e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—atherosclerosis	6.68e-05	0.000134	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—atherosclerosis	6.67e-05	0.000133	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGT—atherosclerosis	6.59e-05	0.000132	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—atherosclerosis	6.54e-05	0.000131	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LEP—atherosclerosis	6.45e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—atherosclerosis	6.45e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—atherosclerosis	6.4e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CAV1—atherosclerosis	6.4e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOA1—atherosclerosis	6.38e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Disease—MAPK3—atherosclerosis	6.37e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—atherosclerosis	6.36e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—atherosclerosis	6.32e-05	0.000126	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—atherosclerosis	6.18e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—atherosclerosis	6.16e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—F2—atherosclerosis	6.09e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKB1—atherosclerosis	5.94e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—atherosclerosis	5.9e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK8—atherosclerosis	5.84e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—atherosclerosis	5.83e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—atherosclerosis	5.8e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—atherosclerosis	5.67e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—INS—atherosclerosis	5.51e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL2—atherosclerosis	5.43e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—atherosclerosis	5.34e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1—atherosclerosis	5.33e-05	0.000107	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—atherosclerosis	5.25e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKB1—atherosclerosis	5.19e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK8—atherosclerosis	5.11e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Immune System—MAPK3—atherosclerosis	5.1e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SERPINE1—atherosclerosis	5.06e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—atherosclerosis	5.04e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—atherosclerosis	4.93e-05	9.84e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—atherosclerosis	4.84e-05	9.66e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—atherosclerosis	4.71e-05	9.42e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MAPK3—atherosclerosis	4.71e-05	9.4e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—atherosclerosis	4.67e-05	9.33e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—atherosclerosis	4.66e-05	9.31e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—atherosclerosis	4.65e-05	9.3e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—atherosclerosis	4.57e-05	9.13e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MAPK3—atherosclerosis	4.46e-05	8.91e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—atherosclerosis	4.33e-05	8.65e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—atherosclerosis	4.3e-05	8.58e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—atherosclerosis	4.29e-05	8.57e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—atherosclerosis	3.88e-05	7.75e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKB1—atherosclerosis	3.84e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK8—atherosclerosis	3.77e-05	7.54e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—atherosclerosis	3.73e-05	7.45e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—atherosclerosis	3.48e-05	6.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—atherosclerosis	3.45e-05	6.89e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—atherosclerosis	3.44e-05	6.88e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—atherosclerosis	3.44e-05	6.87e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MAPK3—atherosclerosis	3.3e-05	6.59e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—atherosclerosis	3.26e-05	6.52e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—atherosclerosis	3.2e-05	6.39e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—atherosclerosis	3.17e-05	6.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—atherosclerosis	3.01e-05	6.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—atherosclerosis	2.41e-05	4.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—atherosclerosis	2.22e-05	4.44e-05	CbGpPWpGaD
